Linganisha mbinu

	Utafiti wa Ikolojia Adaptive	Ubunifu wa Majaribio Unaojirekebisha
Nyanja	Epidemiolojia	Utafiti wa Kliniki
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	1990s–2000s (adaptive extensions of classical ecological designs)	1990s-2000s
Mwanzilishi	Building on classical ecological epidemiology (Durkheim, Snow, Morgenstern); adaptive extensions developed in late 20th–early 21st century methodological literature	Stephen Pocock, Christopher Jennison, and statistical methodologists; FDA formalized guidance 2019
Aina	Observational study design	Research Design
Chanzo asilia	Morgenstern, H. (1998). Ecologic studies. In K. J. Rothman & S. Greenland (Eds.), Modern Epidemiology (2nd ed., pp. 459–480). Lippincott-Raven.	Pocock, S. J. (2005). Current issues in the design and interpretation of clinical trials. BMJ, 330(7500), 1118–1121.
Majina mbadala	adaptive ecologic study, sequential ecological study, adaptive population-level design, adaptive group-level study	adaptive trial, adaptive design, response-adaptive randomization, RAR
Zinazohusiana	3	1
Muhtasari	An adaptive ecological study is an observational epidemiological design in which the unit of analysis is a group or population (e.g., a region, country, or community) rather than an individual. It extends the classical ecological study by incorporating pre-specified interim decision rules that allow modifications — such as changes in geographic unit, time window, or exposure categorisation — as data accumulate, while preserving overall inferential validity. The design is used to explore population-level associations between aggregate exposures and aggregate outcomes.	An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.